Latest From NeuroSystec Corp.
Otonomy has moved two candidates into registration trials for middle and inner ear disorders and plans to have a third ready for the clinic next year.
The 2009 meeting of the American Academy of Ophthalmology showcased the latest developments in cataract/refractive surgery, glaucoma, retina, and other ophthalmic subspecialties. The cataract/refractive surgery market has been under significant economic pressure recently due to a recessionary drop in elective ophthalmic procedures. However, evolving treatments for "back of the eye" conditions, such as age-related macular degeneration (AMD) and diabetic retinopathy, are making significant inroads toward improved patient outcomes for these common and devastating diseases and continue to energize the retina products market.
In Vivo briefly summarizes the technologies of these recently founded companies: Anthera Pharmaceuticals, Genistent Medical, NeuroSystec, Tengion, T-Shift and Vaxon Biotech.
- Implantable Devices
- Site Specific
- Drug Delivery
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- NeuroSystec Corp.
- Senior Management
Stephen J McCormack, PhD, Pres. & CEO
Thomas J Lobl, PhD, VP, R&D
- Contact Info
Phone: (661) 702-6880
25134 Rye Canyon Loop, Ste. 370
Valencia, CA 91355
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.